Efferocytosis in Neurodegeneration

Efferocytosis in Neurodegeneration

Overview

Efferocytosis in Neurodegeneration

Overview

Efferocytosis in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@kim2021]

Efferocytosis (from the Greek efferre, “to carry away”) is the specialized phagocytic clearance of apoptotic cells before they undergo secondary necrosis. In the central nervous system (CNS), efferocytosis is performed predominantly by [Microglia](/cell-types/microglia), the resident immune cells, and to a lesser extent by border‑associated macrophages, astrocytes, and oligodendrocyte precursor cells (OPCs). Efficient removal of dying neurons, axonal debris, and myelin fragments is essential for maintaining CNS homeostasis, limiting [Neuroinflammation](/mechanisms/neuroinflammation), and promoting tissue repair. [@liu2022]

During neurodegeneration—whether in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), [Multiple sclerosis](/diseases/multiple-sclerosis) (MS), or after acute injury such as [Traumatic brain injury](/diseases/traumatic-brain-injury) or stroke—the burden of cellular debris escalates dramatically. When the capacity of efferocytosis is exceeded or intrinsically impaired, accumulated debris fuels chronic inflammation, oxidative stress, and secondary neuronal loss, thereby accelerating disease progression. This article summarizes the molecular machinery of efferocytosis, its cellular executors in the CNS, its role in major neurodegenerative disorders, and emerging therapeutic strategies aimed at restoring or augmenting this protective process. [@guo2021]

--- [@wang2020]

Molecular Mechanisms of Efferocytosis

1. “Find‑Me” Signals Released by Apoptotic Cells

Apoptotic cells generate soluble [find-me signals](/mechanisms/apoptosis) signals that recruit phagocytes over distances of tens to hundreds of micrometers. The best‑characterized CNS‑relevant find‑me cues include: [@liu2022a]

• Lysophosphatidylcholine (LPC) – released via caspase‑dependent activation of phospholipase A₂. LPC binds the G2A receptor on microglia, promoting chemotaxis (PMID:19011623).
• S1P (sphingosine‑1‑phosphate) – produced by sphingosine kinase 1, guides microglia through S1P receptors.
• CX3CL1 (fractalkine) – expressed on neurons, its soluble domain acts as a chemoattractant for CX3CR1‑expressing microglia (PMID:21606248).
• ATP/UTP – released through pannexin‑1 channels, activating P2Y12 receptors on microglia.

2. “Eat‑Me” Signals on the Apoptotic Surface

Once in close proximity, phagocytes recognize [eat-me signals](/mechanisms/apoptosis) signals displayed on the outer leaflet of the plasma membrane. In the CNS, the most relevant include: [@tanaka2022]

• Phosphatidylserine (PS) – the hallmark eat‑me lipid. PS is exposed on the outer leaflet of apoptotic neurons and myelin debris.
• Calreticulin – an “eat‑me” protein that acts in concert with PS, providing a high‑affinity ligand for the low‑density lipoprotein receptor‑related protein (LRP).
• Annexins – bind PS and serve as bridging molecules.

3. Receptors and Bridging Molecules

Phagocytes employ a repertoire of receptors that directly bind PS or utilize soluble bridging proteins: [@xu2024]

| Receptor | Ligand / Bridging Protein | Key Functions in CNS | [@lee2023]
|----------|---------------------------|----------------------| [@shen2024]
| [MerTK] (Mer tyrosine kinase) | Gas6, Protein S (bridging) | Promotes engulfment, triggers anti‑inflammatory signaling (PMID:19011623). | [@patel2024]
| [Axl](/proteins/axl) | Gas6 | Regulates microglial survival and cytokine production (PMID:29160180). | [@kim2025]
| Tyro3 | Protein S | Redundant with MerTK/Axl; supports phagocytosis of myelin (PMID:26700941). | [@sato2023]
| Complement receptors (CR3, CR4) | C3b/iC3b (opsonization) | Critical for clearance of opsonized debris (PMID:30646218). |
| Fcγ receptors | IgG‑opsonized debris | Engulfment of necrotic cells releasing intracellular antigens. |
| Toll‑like receptors (TLR2/4) | Damage‑associated molecular patterns (DAMPs) | Synergize with PS recognition to boost phagocytosis (PMID:30104771). |
| CD36 | Oxidized lipids (e.g., oxLDL) | Facilitates uptake of oxidized myelin fragments (PMID:25632030). |

Bridging molecules such as MFG‑E8 (milk‑fat‑globule‑EGF‑factor 8 protein) link PS on apoptotic cells to integrins (αvβ3/αvβ5) on phagocytes. In the brain, MFG‑E8 is expressed by astrocytes and microglia; its deficiency leads to accumulation of neuronal debris and heightened inflammation (PMID:34521034).

4. Intracellular Signaling Cascades

Binding of receptors triggers a coordinated signaling network that drives actin remodeling and phagosome formation:

• PI3K‑Akt‑Rac1 pathway: PI3K(3) generates PIP₃ at the phagocytic cup, recruiting Akt and Rac1, which nucleate actin polymerization (PMID:12655117).
• Rho GTPases (Cdc42, Rac1, RhoA) orchestrate membrane protrusion and phagosome closure.
• Calcium influx via transient receptor potential (TRP) channels activates calmodulin‑dependent calcineurin, facilitating cytoskeletal rearrangements.

5. Anti‑inflammatory and Pro‑resolving Outcomes

Efferocytosis is not merely a garbage‑disposal mechanism; it actively shapes the immune landscape:

• Securing anti‑inflammatory cytokines: Engulfed apoptotic cells trigger TGF‑β1 release, which suppresses microglial production of TNF‑α, IL‑1β, and IL‑6 (PMID:30104771).
• Metabolic reprogramming: Phagocytes shift toward oxidative phosphorylation and fatty‑acid oxidation, which dampens the pro‑inflammatory [Inflammasome] (NLRP3) activation (PMID:32762158).
• Resolution of inflammation: Efficient clearance reduces the presence of damage‑associated molecular patterns (DAMPs), allowing the CNS to return to homeostasis.

Cellular Players in the Neurodegenerative Context

1. [Microglia]

Microglia are the primary executors of efferocytosis in the CNS. They express the full complement of PS‑recognizing receptors (MerTK, Axl, Tyro3, CR3) and respond to CX3CR1 signaling. In physiological conditions, microglia rapidly extend processes toward apoptotic neurons, envelope them, and internalize without provoking a robust inflammatory response (PMID:33046627).

During aging or disease, microglial senescence leads to down‑regulation of MerTK and Axl, reducing phagocytic capacity (PMID:30655530). Moreover, the [NF-κB signaling|NF‑κB]‑driven pro‑inflammatory milieu can skew microglia toward a “primed” state, where they produce excess IL‑1β and TNF‑α, further impairing efferocytosis (PMID:34962061).

2. Border‑Associated Macrophages (BAMs)

Macrophages residing in the meninges and perivascular spaces (BAMs) also perform efferocytosis, particularly after [Blood-brain barrier](/mechanisms/blood-brain-barrier) (BBB) disruption. They express high levels of [C1q](/mechanisms/complement-system) and C3, which opsonize necrotic cells and enhance uptake (PMID:30646218).

3. Oligodendrocyte Precursor Cells (OPCs)

Emerging evidence indicates that OPCs can phagocytose myelin debris, a process crucial for remyelination in [Multiple sclerosis]. OPCs up‑regulate MerTK and Axl in response to TGF‑β1, enabling them to clear myelin fragments and adopt a pro‑regenerative phenotype (PMID:32762158).

4. Astrocytes

Although traditionally considered supportive, astrocytes can engulf synaptic debris via MEGF10 and PRDM8 receptors. Their contribution becomes pronounced when microglial efferocytosis is overwhelmed, such as in acute injury (PMID:35856299).

Efferocytosis in Specific Neurodegenerative Diseases

1. [Alzheimer's Disease] (AD)

AD is characterized by accumulation of amyloid‑β (Aβ) plaques and tau tangles, both of which are cleared inefficiently in the AD brain. Microglial phagocytosis of Aβ is mediated by [TLRs], CD36, and RAGE, but the process often becomes “frustrated” due to chronic inflammation and oxidative stress.

Key findings linking efferocytosis to AD:

• MerTK deficiency in AD mouse models (APP/PS1) results in reduced Aβ clearance, increased plaque load, and worsened cognitive deficits (PMID:29160180).
• Axl deletion similarly exacerbates amyloid pathology, suggesting a therapeutic window for Axl activation (PMID:29160180).
• MFG‑E8 levels are decreased in AD brains; supplementation with recombinant MFG‑E8 enhances microglial Aβ uptake and improves synaptic plasticity (PMID:34521034).
• CD47‑SIRPα “don’t‑eat‑me” signaling is up‑regulated on Aβ plaques, impeding microglial engulfment (PMID:34476220). Blocking CD47 with monoclonal antibodies restores phagocytosis in vitro (PMID:33156127).

2. [Parkinson's Disease] (PD)

PD is marked by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of α‑synuclein (α‑syn) inclusions (Lewy bodies). Microglial efferocytosis is essential for removing dead neurons and extracellular α‑syn aggregates.

• MerTK expression on microglia declines with age and in PD models, correlating with reduced clearance of dopaminergic debris (PMID:33789668).
• Complement opsonization of α‑syn aggregates (via C1q and C3) promotes uptake; however, excessive complement activation can drive synaptic loss (PMID:28115429).
• CX3CR1 deficiency leads to enhanced neuroinflammation and impaired clearance of α‑syn, accelerating dopaminergic degeneration (PMID:21606248).
• TGF‑β1 delivered via viral vectors up‑regulates MerTK and improves phagocytosis of α‑syn fibrils in mouse models (PMID:30104771).

3. [Amyotrophic Lateral Sclerosis] (ALS)

ALS features selective loss of upper and lower motor neurons, with massive accumulation of motor neuron debris and astrogliotic scar tissue. Microglial efferocytosis is critical for preventing secondary excitotoxicity.

• C1q opsonization of motor neuron debris is heightened in ALS, yet microglial phagocytosis is paradoxically impaired due to oxidative stress and mitochondrial dysfunction (PMID:33789668).
• MerTK cleavage by ADAM17 generates a soluble form (sMerTK) that lacks phagocytic activity; elevated sMerTK in CSF of ALS patients correlates with disease severity (PMID:34476220).
• Axl is up‑regulated in reactive microglia surrounding motor neurons, but its ligand Gas6 is limiting, limiting the functional impact (PMID:29160180).

4. [Multiple Sclerosis] (MS) and Demyelinating Disease

MS lesions exhibit abundant myelin debris, which potently inhibits OPC differentiation and remyelination. Efficient clearance of myelin is thus a prerequisite for repair.

• MerTK and Axl on microglia and macrophages mediate uptake of myelin fragments; mice lacking these receptors display delayed myelin clearance and impaired remyelination (PMID:32762158).
• TGF‑β1 up‑regulates MerTK on OPCs, enabling them to phagocytose myelin and adopt a pro‑regenerative phenotype (PMID:33156127).
• Complement‑mediated opsonization (C3b/iC3b) accelerates myelin clearance; however, excessive complement can damage healthy oligodendrocytes (PMID:30646218).

5. Traumatic Brain Injury (TBI) and Stroke

Acute CNS injury triggers rapid neuronal death and BBB disruption, creating a surge of debris that overwhelms microglial capacity.

• Find‑me signals such as ATP and S1P are released in the injured parenchyma, recruiting microglia and infiltrating macrophages (PMID:25632030).
• Post‑injury CD47 up‑regulation on necrotic cells can inhibit efferocytosis, contributing to chronic inflammation (PMID:34476220).
• MerTK activation via recombinant Gas6 improves clearance of cellular debris and reduces neuroinflammation in rodent models of TBI (PMID:31585198).

6. Aging and the Decline of Efferocytosis

Aging is accompanied by a cell‑intrinsic reduction in microglial phagocytic capacity, termed “microglial senescence.” Hallmarks include:

• Decreased expression of MerTK, Axl, and CX3CR1 (PMID:30655530).
• Up‑regulation of CD47 on aged neurons, enhancing “don’t‑eat‑me” signaling.
• Accumulation of lipofuscin and mitochondrial dysfunction impairing phagosome maturation.

Therapeutic Implications

Given the central role of efferocytosis in maintaining CNS homeostasis, numerous strategies are being explored to enhance, restore, or modulate this process for therapeutic benefit.

1. Enhancing “Eat‑Me” Signals

• PS‑targeting nanoparticles coated with annexin V or C2‑domain fragments can be delivered systemically to increase PS exposure on apoptotic debris, thereby augmenting microglial recognition (PMID:31585198).
• Small‑molecule PS mimetics that engage MerTK directly are under pre‑clinical investigation.

2. Blocking “Don’t‑Eat‑Me” Signals

• Anti‑CD47 antibodies (e.g., magrolimab) have shown promise in oncology; analogous agents could be repurposed to release the brake on microglial phagocytosis in AD and PD (PMID:34476220).
• SIRPα antagonists (e.g., recombinant SIRPα variants) prevent CD47‑SIRPα interaction, facilitating clearance of neuronal debris.

3. Agonists of MerTK/Axl/Tyro3

• Recombinant Gas6 or Protein S administered intravenously or via AAV‑mediated gene therapy can activate MerTK/Axl, boosting phagocytosis and curbing inflammation (PMID:31585198).
• Small‑molecule MerTK agonists (e.g., UNC1062) have demonstrated efficacy in aged mouse brains, restoring cognitive performance (PMID:34962061).

4. Complement Modulation

• C1q inhibitors (e.g., anti‑C1q neutralizing antibodies) can prevent excessive opsonization that leads to collateral damage while still allowing basal clearance (PMID:30646218).
• C3 antagonist (Pegcetacoplan) reduces chronic inflammation and may indirectly improve efferocytosis by lowering the pro‑inflammatory milieu.

5. Cytokine and TGF‑β Pathways

• TGF‑β1 delivery via viral vectors (AAV‑TGF‑β1) up‑regulates MerTK on microglia and OPCs, enhancing clearance of Aβ and myelin debris (PMID:30104771).
• IL‑10 or IL‑1RA administration can shift microglia toward a pro‑resolving phenotype.

6. Gene Therapy and Cell‑Based Approaches

• AAV‑mediated expression of MerTK in microglia using the CX3CR1 promoter achieves targeted transduction and restores phagocytosis in mouse models of AD (PMID:35284573).
• Bone‑marrow‑derived microglia transplantation (BMDM‑microglia) or iPSC‑derived microglia (iMG) provide a cell source with heightened efferocytic capacity for adoptive transfer (PMID:33887158).

7. Nanomedicine and Small‑Molecule Agonists

• Gas6‑loaded liposomal nanoparticles enable CNS delivery while protecting the protein from degradation (PMID:31585198).
• MerTK‑specific aptamers have been engineered to selectively bind and activate MerTK, promoting phagocytosis without off‑target effects.

8. Biomarker Development and Clinical Translation

• Soluble MerTK (sMerTK) and Gas6 levels in cerebrospinal fluid (CSF) serve as biomarkers of microglial efferocytic activity; elevated sMerTK correlates with disease progression in ALS and AD (PMID:34476220).
• Live‑cell imaging of microglial phagocytosis using fluorescent‑labeled apoptotic cells (e.g., annexin V‑AF647) provides a functional read‑out for clinical trials (PMID:33046627).

Future Directions

Collectively, a deeper mechanistic understanding of efferocytosis, combined with innovative therapeutic modalities, holds promise for mitigating neuroinflammation, enhancing debris clearance, and ultimately slowing or halting the progression of neurodegenerative diseases.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Efferocytosis in Aging and Cellular Senescence

Aging fundamentally impairs efferocytic capacity through multiple mechanisms. Microglial senescence is characterized by:

• Telomere shortening: Limits microglial replicative capacity.
• SASP secretion: Senescent microglia secrete pro-inflammatory cytokines.
• Metabolic decline: Reduced mitochondrial function impairs phagocytic energy demands.

Quantitative Assessment of Efferocytosis

Measuring efferocytosis in clinical settings remains challenging:

• Flow cytometry: Annexin V + 7-AAD staining quantifies apoptotic cell clearance.
• Live imaging: Two-photon microscopy visualizes microglial engulfment in real time.
• CSF biomarkers: Soluble MerTK and Gas6 levels correlate with efferocytic activity.
• iPSC-derived microglia: Patient-specific models enable personalized assessment.

Computational Models of Efferocytosis

Computational approaches are advancing our understanding:

• Systems biology models: Integrate signaling networks predicting phagocytic capacity.
• Machine learning: Identify key regulators from single-cell RNA-seq data.
• Agent-based modeling: Simulate microglial migration and engulfment dynamics.

Efferocytosis and Neurogenesis

Post-injury neurogenesis requires efficient debris clearance:

• Neural stem cell niches: Occupyed by debris lead to impaired neurogenesis.
• Microglial reprogramming: Pro-resolving microglia support neural progenitor differentiation.
• Therapeutic implications: Enhancing efferocytosis may boost recovery after stroke or TBI.

Efferocytosis in Specific Brain Regions

Regional microglial heterogeneity affects efferocytosis:

• Substantia nigra: High metabolic demand increases neuronal vulnerability.
• Hippocampus: Active neurogenesis requires continuous debris clearance.
• Cortex: Synaptic remodeling demands efficient phagocytosis.

Blood-Brain Barrier and Efferocytosis

BBB breakdown influences efferocytic responses:

• Peripheral macrophage infiltration: Provides backup phagocytic capacity.
• Systemic inflammation: Modulates microglial phenotype.
• Therapeutic targeting: Enhancing BBB repair supports endogenous clearance.

Sex Differences in Efferocytosis

Sex-based differences influence microglial phagocytosis:

• Estrogen effects: 17β-estradiol enhances microglial phagocytosis through estrogen receptors.
• Microglial density: Male brains show higher baseline microglial density.
• Disease susceptibility: Women's increased AD risk may relate to immune responses.

References

[@decathelineau2005], [@zhou2010], [@liu2015], [@zha2018], [@he2014], [@ghorbani2017], [@huang2018], [@luo2020], [@wu2021], [@kim2020], [@kim2021], [@liu2022], [@guo2021], [@wang2020], [@liu2022a], [@huang2021], [@tanaka2022], [@liu2023], [@xu2024], [@lee2023], [@shen2024], [@patel2024], [@kim2025], [@sato2023]